跳至主要内容
临床试验/CTRI/2025/08/092536
CTRI/2025/08/092536已完成Unknown

An Open-Label Pilot Study to Evaluate the Effects and Safety of the Satiety-Enhancing Topical Formulation TDW on Cravings and Satiety in Obese Adults.

Urrth Naturals LLP1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年8月18日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
1 Improvement in satiety (measured by New Zealand Eating Behavior Questionnaire (NZ EBQ)

研究概览

简要总结

This is an open-label pilot clinical study designed to assess the effects and safety of a topical formulation, TDW, intended to enhance satiety and reduce food cravings in obese adults. The study will evaluate changes in self-reported satiety levels and cravings over the treatment period, along with monitoring for any adverse effects to determine the product’s tolerability and feasibility for further clinical development.

研究设计

研究类型
Observational

入排标准

年龄范围
25.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • To participate in the study subjects must meet the following criteria 1 Age Male and female participants aged 25 to 60 years 2 Body Mass Index (BMI) BMI between 30.0 to 34.9 kilograms per square meter (Class I obesity) 3 Physical Activity Engaging in at least 30 minutes of moderate physical activity per day on most days of the week five or more days per week, and willing to maintain this activity level throughout the study period 4 Subjective Satiety Dysfunction Participants who score less than or equal to 19 on the Satiety Subscale of the New Zealand Eating Behaviour Questionnaire (NZ-EBQ) indicating moderate to poor satiety regulation 5 High Food Cravings Participants who score greater than or equal to 70 millimeters on VAS for Desire to Eat or Hunger OR self-report persistent cravings for unhealthy snacks despite regular meals 6.Subjective Hunger Index Baseline VAS score for Hunger greater than or equal to 60 millimeters out of 100 mm indicating elevated appetite levels.
  • 7 Motivated for Diet Control Participants who selfreport difficulty adhering to a diet despite efforts at weight loss or dietary regulation 8 Consent and Compliance Willing and able to provide written informed consent and comply with all study procedures including daily application of the patch and completion of appetite mood questionnaires.

排除标准

  • A subject will be considered unsuitable for the study if they meet any one of the following criteria: 1 Use of appetite suppressants or weight loss medications 2 Presence of metabolic disorders eg diabetes thyroid disease 3 Significant skin conditions or known allergies especially those that may interfere with topical applications 4 Recent participation in any weight loss programs or clinical trials 5 Pregnancy or lactation 6 Current smokers 7 Heavy alcohol consumption.

结局指标

主要结局

1 Improvement in satiety (measured by New Zealand Eating Behavior Questionnaire (NZ EBQ)

时间窗: Visit-1 | Screening | (Day 0) Baseline | Visit-2 | (Day 15) + 2 days | Visit-3 and EOS | (Day 45) + 2 days

2 Reduction in cravings for snacking:

时间窗: Visit-1 | Screening | (Day 0) Baseline | Visit-2 | (Day 15) + 2 days | Visit-3 and EOS | (Day 45) + 2 days

1 measured by Snacking Craving Scale Validated 3 Item VAS

时间窗: Visit-1 | Screening | (Day 0) Baseline | Visit-2 | (Day 15) + 2 days | Visit-3 and EOS | (Day 45) + 2 days

2 measured by Visual Analogue Scale VAS Appetite Assessment

时间窗: Visit-1 | Screening | (Day 0) Baseline | Visit-2 | (Day 15) + 2 days | Visit-3 and EOS | (Day 45) + 2 days

次要结局

  • 1 Change in mood measured by Profile of Mood States POMS(2 Change in perceived stress measured by Perceived Stress Scale PSS)

研究者

发起方
Urrth Naturals LLP
申办方类型
Other [nutraceutical]
责任方
Principal Investigator
主要研究者

DrDipti Gupta

Tulsi Multispeciality Hospital.

研究点 (1)

Loading locations...

相似试验